Journal of Rheumatic Diseases

Table. 5.

DMARDs at recent outpatient clinic visits (n=25)*

DMARDs prescription patterns Prescribed DMARDs
No DMARD (n=4)
csDMARDs (n=14)
Monotherapy (n=3) MTX (n=3)
Combination (n=11) MTX (+) (n=8) MTX+HCQ (n=1), MTX+HCQ+SSZ (n=1), MTX+TC (n=1), MTX+LEF (n=5)
MTX (–) (n=3) LEF+HCQ (n=1), SSZ+TC (n=1), SSZ+HCQ (n=1)
Biologics (n=7) MTX (+) (n=3) ADA (n=1), TCZ (n=1), ABA (n=1)
MTX (–) (n=4) ETA (n=2), TCZ (n=2)

DMARDs: disease modifying anti-rheumatic drugs, csDMARDs: conventional synthetic DMARDs, MTX: methotrexate, SSZ: sulfasalazine, HCQ: hydroxychloroquine, TC: tacrolimus, LEF: leflunomide, ADA: adalimumab, TCZ: tocilizumab, ABA: abatacept, ETA: etanercept, IQR: interquartile range. *At a median of 4.6 years (IQR 3.3, 6.7) after cancer diagnosis, five patients died (four out of 13 in the discontinuation group and one out of 27 in the switching or maintenance group) and 10 patients were lost (two out of 13 in the discontinuation group and eight out of 27 in the switching or maintenance group). †Three had cancer recurrence after chemotherapy and one achieved arthritis remission after cancer treatment.

J Rheum Dis 2022;29:162~170 https://doi.org/10.4078/jrd.2022.29.3.162
© J Rheum Dis